Study shows protective effect of Medicaid expansion on early-stage cancer diagnosis

-

 


The COVID-19 pandemic disrupted health care, including cancer screening and diagnosis, especially for medically underserved populations, leading to substantial underdiagnosis of early-stage cancers in 2020. In a new study led by the American Cancer Society (ACS), scientists found that Medicaid expansion was associated with smaller declines in early-stage cancer detection among adults during the pandemic. The study is to be published today in the Journal of the National Cancer Institute (JNCI).

For the study, researchers compared changes in proportions of early-stage (stage I/II) cancer diagnosis in Medicaid expansion states versus non-expansion states. Scientists analyzed data among 1,844,515 individuals aged 18-64 years newly diagnosed with cancer in 2018-2022 from the National Cancer Database using a difference-in-differences (DD) approach. Adjusted DD estimates were calculated and stratified by key sociodemographic factors and cancer type.

The results showed that the uninsured percentage among patients aged 18-64 years newly diagnosed with cancer remained stable at around 2% in Medicaid expansion states and an estimated 8% in non-expansion states. The proportion of early-stage diagnoses declined following the COVID-19 pandemic, but the decline was considerably smaller in Medicaid expansion states than in non-expansion states, particularly pronounced among patients aged 18-44 years, patients who are male with high comorbidity burden, and treated in academic facilities; the populations who were most likely to obtain insurance coverage through Medicaid expansion.

"Our findings can inform policymakers and the public in the 10 states that have yet to expand Medicaid eligibility," Han added. "The findings also provide critical information for policymakers and the public in all states about the public health implications of upcoming large federal cuts to Medicaid programs and expected loss of insurance coverage for more than 10 million adults."

"This research adds to the mountain of existing proof that Medicaid expansion saves lives from cancer by reducing the number of people who are uninsured," said Lisa A. Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of ACS. "ACS CAN has long advocated for Medicaid expansion, and our work continues as states begin to contemplate how to implement the drastic changes from this summer's budget reconciliation law. These recent changes made by Congress to cut Medicaid will undo decades of progress in the fight against cancer. Increasing and protecting existing access to this critical program must be a priority nationwide if we are to end cancer as we know it, for everyone." Other ACS researchers contributing to the study include Nova Yang, MSPH, Dr. Qinjin Fan, Dr. Leticia Nogueira, Dr. Ahmedin Jemal, and senior author Dr. Robin Yabroff.

#ResearchChemistry, #ChemicalInnovation, #Science, #ScienceResearch, #ScientificResearch, #ResearchAndDevelopment, #ChemistryEducation, #ChemistryExperiments, #ChemistryLab, #ChemistryStudents, #ChemistryStudy, #OrganicChemistry, #InorganicChemistry, #PhysicalChemistry, #AnalyticalChemistry, #Biochemistry, #MaterialsChemistry, #TheoreticalChemistry, #AppliedChemistry, #MedicinalChemistry

Comments

Post a Comment

Popular posts from this blog

Avoiding prostate cancer screening increases risk of death

-
Image
  Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group. An analysis of data from across seven countries from the world's largest prostate cancer screening study, the European Randomized study of Screening for Prostate Cancer (ERSPC), is presented this weekend at the European Association of Urology (EAU) Congress in Madrid. Prostate cancer is the most common form of cancer in men in 112 countries, with prevalence expected to double by 2040. If introduced on a national scale, prostate cancer screening programmes that measure levels of prostate-specific antigen (PSA) in the blood have the potential to give men earlier access to treatment, a better chance of being cured. They can also prevent costly treatment associated with advanced prostate cancer. Long-term follow-up data from the ERSPC consistently report that PSA screening programmes can lead to a 20% re...
Read more

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

-
Image
  Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, crafting what they have named the "EchoBack CAR T-cell," which could soon be a game changer in the field of cancer immunotherapy . The work, published in the scientific journal Cell, is a groundbreaking new approach that could overcome major obstacles in treating tumors that are not usually candidates for immunotherapy, while keeping healthy tissue safe. Chimeric antigen receptor (CAR) T-cell therapy is a promising field of cancer treatment that has shown great success in treating bloodborne cancers such as leukemia. It is a highly customized therapy in which cancer-fighting T-cells are drawn directly from the blood of a patient and given genetic modifications to enhance their ability to target and kill cancerous cells. The USC Alfred E. Mann Department ...
Read more

The Role of Analytical Chemistry in Industry and Manufacturing

-
Image
Industry and the manufacturing sector use multiple analytical chemical methods, whether for new product development, processing, or quality control. This article outlines the research to be presented at Pittcon on the advances being made in analytical chemistry and their application in industry and manufacturing. Spectroscopy is a valuable analytical tool for a wide range of sectors. Several talks will focus on Raman spectroscopy as a highly versatile analytical tool, which can be used in chemical processing from laboratory to manufacturing. Raman spectroscopy’s use in polymer science to measure and control chemical processes is a particular focus. The technique is becoming increasingly relevant as chemical manufacturing expands to include new developments such as batch reactions, microreactors, flow synthesis, and continuous processes. Pittcon will hear examples of using Raman spectroscopy to improve process efficiency and predict reaction end-times and physical properties of chemical...
Read more